News

TPI-287 study includes patients with disease metastatic to the brain as the drug, avoids the multidrug resistant (MDR) efflux pump and has demonstrated in pre-clinical studies its ability

Biomoda’s CyPath reagents for the early detection of cancers is based on meso-tetra (4 carboxyphenyl) porphine (TCPP), a porphyrin compound that binds to cancer cells and fluoresces under

Prolor said that hGH is its proprietary biobetter version of human growth hormone. The Phase II study was commenced to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic properties

Ampio Pharma claimed that Optina is a repurposed oral drug with an established human safety profile. Pre-clinical studies have shown the potential for Optina to reduce diabetic macular

The agreement gives Sysmex a non-exclusive right to sell CellaVision’s products in hematology laboratories worldwide. As of April 1, 2010, the non-exclusive agreement comprises all international markets except

The project is being undertaken in collaboration with Sam Gunderson and Rafal Goraczniak at SilaGene (Hillsborough, NJ), a newly formed biotechnology company working on U1 Adapter therapeutics. IDT

In a Phase2 pilot study, Itraconazole topical suspension was shown to be effective in the treatment of FOE with no adverse events reported. Fera Pharma is working to

The partnership calls for SDIX to collaborate with Banyan on the development of antibodies and immuno-solutions that include custom monoclonal and polyclonal antibody development, cell line banking and

Prior to joining Catalent Pharma Mr Booth worked as president and chief operating officer of Medimmune, from 1998 through his retirement in 2003, and as a director from